@CandelTx Candel Therapeutics

Candel Therapeutics posts on X about $cadl, ceo, we are, in the the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

• [--] Week [-----] -57%
• [--] Month [------] +251%
• [--] Months [------] -4%
• [--] Year [------] -6.30%

Mentions: [--] #

• [--] Week [--] -26%
• [--] Month [--] +920%
• [--] Months [--] +91%
• [--] Year [--] +21%

Followers: [---] #

• [--] Week [---] +0.28%
• [--] Month [---] +2%
• [--] Months [---] +12%
• [--] Year [---] +36%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 46.43% finance 8.93% exchanges 2.68% travel destinations 2.68% financial services 1.79% countries 0.89%

Social topic influence $cadl #2, ceo 21.43%, we are 13.39%, in the 9.82%, platform 5.36%, future 4.46%, brain 4.46%, hope 3.57%, company 3.57%, nasdaq 2.68%

Top accounts mentioned or mentioned by @paulpetertak @nasdaq @jefferies @citeline @sitcancer @muralidharan125 @routeco145 @nnchamber @pharmavoice @urologytimes @zerocancer @westorg @charuaggarwalmd @penn @jpmorgan @baroneexpmed @eachiocca @wcvb @brighamwomens @longwoodleaders

Top assets mentioned Candel Therapeutics, Inc. (CADL) Trinity Capital Inc. (TRIN)

Top Social Posts

Top posts by engagements in the last [--] hours

"Congratulations to our very own Dr. Estuardo Aguilar-Cordova for being picked by @nnchamber as one of the [--] Most Influential Business People of Color #Immunotherapy #oncology #GMCI https://www.nnchamber.com/bpoc-list/estuardo-aguilar-cor https://www.nnchamber.com/bpoc-list/estuardo-aguilar-cor"
X Link 2020-11-14T23:17Z [---] followers, [--] engagements

"Pharma veteran and renowned immunologist @paulpetertak has joined Candel as our new CEO. Were also expanding our leadership team with new appointments including CFO CBO and CRO. Get the full details in our press release: https://www.businesswire.com/news/home/20201208005304/en/Candel-Therapeutics-Appoints-Pharma-Veteran-and-Immunologist-Paul-Peter-Tak-M.D.-Ph.D.-as-Chief-Executive-Officer-Expands-Leadership-Team-With-Chief-Financial-Officer-Chief-Business-Officer-and-Chief-Regulatory-Officer-Appointments"
X Link 2020-12-08T13:10Z [---] followers, [--] engagements

"Today marks our one year anniversary on @Nasdaq We're extremely proud and grateful for our team members and supporters who helped us achieve this important milestone. Together we can work to create a better future for people diagnosed with cancer"
X Link 2022-07-27T16:04Z [---] followers, [--] engagements

"This #WorldCancerDay our commitment remains clear: developing innovative immunotherapies that harness each patients own immune system to fight cancer. Were advancing two clinical-stage immunotherapy platforms targeting some of cancers toughest challenges"
X Link 2026-02-04T15:00Z [---] followers, [---] engagements

"Watch our CEO @paulpetertak discuss the promising phase 2a results of CAN-2409 in pancreatic cancer showing median overall survival of [----] months vs [----] months in the control group with [--] patients still alive after extended follow-up. $CADL https://www.proactiveinvestors.com/companies/news/1067175/candel-therapeutics-ceo-discusses-promising-phase-2-pancreatic-cancer-trial-results-icymi-1067175.html https://www.proactiveinvestors.com/companies/news/1067175/candel-therapeutics-ceo-discusses-promising-phase-2-pancreatic-cancer-trial-results-icymi-1067175.html"
X Link 2025-04-21T15:34Z [---] followers, [----] engagements

"We're pleased to announce Candel's participation in two investor conferences. We look forward to discussing our innovative viral immunotherapies & clinical progress with the investment community. See todays release for details: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences"
X Link 2025-05-06T12:31Z [---] followers, [----] engagements

"Were participating in the H.C. Wainwright Annual Global Investment Conference. With $100.7 million in cash as of June [--] [----] were well-positioned to fund operations into Q1 [----] and execute on key value-creating milestones. $CADL #HCWainwright https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-participate-upcoming-investor-conferences"
X Link 2025-09-08T13:05Z [---] followers, [----] engagements

"Well be at #SITC2025 Presenting posters on our enLIGHTEN platform and CAN-2409 in NSCLC plus our CEO @paulpetertak will speak on our phase [--] prostate cancer data. See the curtain raiser: #Immunotherapy #ProstateCancer #NSCLC https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-sitc-2025-annual-meeting https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-sitc-2025-annual-meeting"
X Link 2025-10-03T13:10Z [---] followers, [---] engagements

"October is National Healthy Lung Month. Our CAN-2409 NSCLC program shows promise: [----] months median survival vs 9.8-11.8 months with standard treatment in patients with progressive disease. Lung cancer claims 1.8M+ lives annually. Every breakthrough matters. #HealthyLungMonth"
X Link 2025-10-13T14:00Z [---] followers, [---] engagements

"November is #LungCancerAwareness Month. Our CAN-2409 NSCLC program shows promise: [----] months median survival in ICI-refractory patients vs [--] months with standard of care chemotherapy. Lung cancer claims 1.8M+ lives annually. Every breakthrough matters. https://candeltx.com/patients/#step-25 https://candeltx.com/patients/#step-25"
X Link 2025-11-03T15:39Z [---] followers, [----] engagements

"#ICYMI - We secured a $130M term loan facility with Trinity Capital strengthening our runway through key milestones: - BLA submission Q4 [----] - Commercial launch prep - NSCLC pivotal studies Q2 [----] $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-enters-130-million-term-loan-facility https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-enters-130-million-term-loan-facility"
X Link 2025-11-11T15:00Z [---] followers, [----] engagements

"#ICYMI - Our Q3 financial results highlighted the significant progress across our cancer immunotherapy pipeline. From clinical advancements to strategic financing were positioning Candel for continued growth. Read more here: #CADL https://www.proactiveinvestors.com/companies/news/1082445/candel-therapeutics-highlights-3q-milestones-across-cancer-immunotherapy-pipeline-1082445.html https://www.proactiveinvestors.com/companies/news/1082445/candel-therapeutics-highlights-3q-milestones-across-cancer-immunotherapy-pipeline-1082445.html"
X Link 2025-12-08T15:00Z [---] followers, [----] engagements

"Thank you to @PharmaVoice for including our CEO @paulpetertak among industry leaders sharing their outlook for pharma in [----]. Dr. Tak shares his perspective on why adaptability will define successful commercialization strategies moving forward. https://www.pharmavoice.com/news/pharma-crystal-ball-2026-predictions-regulations-policy-market/808688/ https://www.pharmavoice.com/news/pharma-crystal-ball-2026-predictions-regulations-policy-market/808688/"
X Link 2026-02-02T15:00Z [---] followers, [----] engagements

"We are pleased to announce Dr. Bali Pulendran joins Candels Research Advisory Board. Dr. Pulendran is a leading systems immunology expert and Professor at Stanford. $CADL #Advisory https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-leading-systems-immunology-expert https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-leading-systems-immunology-expert"
X Link 2025-10-16T12:09Z [---] followers, [----] engagements

"Its Brain Tumor Awareness Week. Our CAN-3110 program targets recurrent high-grade glioma with oncolytic HSV approach. We are working hard to advance treatment options for challenging brain cancers. $CADL #BrainTumorAwareness"
X Link 2025-10-28T16:01Z [---] followers, [----] engagements

"We are seeing steady advancement across our pipeline and look forward to continued momentum as we head into [----]. Learn about the Q3 progress and anticipated plans for the rest of the year in the Q3 [----] financial press release: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2025-financial-results https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2025-financial-results"
X Link 2025-11-13T13:32Z [---] followers, [----] engagements

"Our CEO @paulpetertak will share the latest corporate updates at the @Jefferies London Healthcare Conference this week. See the details here: $CADL #JefferiesHealthcare https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-jefferies-global-healthcare-0 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-jefferies-global-healthcare-0"
X Link 2025-11-17T15:01Z [---] followers, [----] engagements

"Were hosting a Virtual R&D Day to discuss our cancer immunotherapy pipeline. The #event will feature insights from leading experts as we discuss the future of #cancer treatment. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-event-december-5-2025 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-event-december-5-2025"
X Link 2025-12-02T15:01Z [---] followers, [----] engagements

"#TBT to last month when Candel was honored with the [----] Scrip Award for Best Oncology R&D Advance This recognition celebrates our successful phase [--] study of CAN-2409 in localized prostate cancer. Thank you to @Citeline for this honor. $CADL https://citeline.com/en/awards/scripawards https://citeline.com/en/awards/scripawards"
X Link 2026-01-09T15:00Z [---] followers, [----] engagements

"Read this article highlighting our viral immunotherapy approach and promising clinical results across multiple solid tumors. It covers our positive phase [--] data in prostate cancer and our plans to file a BLA for CAN-2409 in late [----]. $CADL https://www.nature.com/articles/d43747-025-00101-6 https://www.nature.com/articles/d43747-025-00101-6"
X Link 2026-01-12T15:00Z [---] followers, [----] engagements

"#ICYMI - Our Virtual R&D Day brought together immunotherapy legends alongside leading oncologists to discuss our viral immunotherapy platform CAN-2409s path to BLA submission and updates across our clinical pipeline. Watch the full webcast $CADL https://ir.candeltx.com/events/event-details/candel-therapeutics-host-virtual-rd-event https://ir.candeltx.com/events/event-details/candel-therapeutics-host-virtual-rd-event"
X Link 2026-01-21T15:00Z [---] followers, [----] engagements

"NSCLC remains challenging to treat. Our viral immunotherapy CAN-2409 showed encouraging results in phase [--] achieving [--] months median overall survival vs. [--] months reported in the literature for second-line chemotherapy. Next is phase [--] trial initiation in Q2 [----]. $CADL"
X Link 2026-01-27T15:00Z [---] followers, [----] engagements

"Our phase [--] trial of CAN-2409 in intermediate-to-high-risk localized prostate cancer showed a 30% improvement in disease-free survival and 80% complete pathological response vs. 64% in controls. BLA submission planned for Q4 [----]. $CADL https://candeltx.com/ https://candeltx.com/"
X Link 2026-01-29T15:00Z [---] followers, [----] engagements

"Were excited to share that our Chief Scientific Officer Francesca Barone will be presenting at the 7th Glioblastoma Drug Development Summit next week in Boston. #Glioblastoma #CancerResearch https://glioblastoma-drugdevelopment.com/speaker/francesca-barone/ https://glioblastoma-drugdevelopment.com/speaker/francesca-barone/"
X Link 2026-02-10T15:00Z [---] followers, [---] engagements

"Well be sharing data from our CAN-2409 program in NSCLC & and our enLIGHTEN Discovery Platform. Our CEO @paulpetertak will give a presentation on the phase [--] clinical trial of CAN-2409 in prostate cancer. More details: https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-immunotherapy-leadership-sitc-2025 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-immunotherapy-leadership-sitc-2025"
X Link 2025-11-04T14:16Z [---] followers, [----] engagements

"Dr. Glen Gejerman spoke to @UrologyTimes about Candels phase [--] trial results for CAN-249 in localized intermediate- to high-risk prostate cancer presented at ASTRO [----]. Tune into this insightful video to hear more. https://www.urologytimes.com/view/glen-gejerman-md-highlights-phase-3-data-on-can-2409-in-localized-prostate-cancer https://www.urologytimes.com/view/glen-gejerman-md-highlights-phase-3-data-on-can-2409-in-localized-prostate-cancer"
X Link 2025-12-10T15:00Z [---] followers, [----] engagements

"As [----] draws to a close we reflect on what an incredible year it has been. Were grateful for our dedicated team supportive partners and the patients who inspire our mission every day. Wishing everyone peace joy and continued optimism in the fight against cancer"
X Link 2025-12-23T15:59Z [---] followers, [---] engagements

"Next week our executive team will be in San Francisco for the J.P. Morgan Healthcare Conference. We look forward to connecting with industry leaders and the investor community. Hope to see you there #JPM2026 #Healthcare #Biotech $CADL"
X Link 2026-01-06T15:00Z [---] followers, [----] engagements

"Were excited to join the @Nasdaq family Now #NasdaqListed and trading: $CADL. Learn more about our IPO here: https://bit.ly/3i5UcnL https://bit.ly/3i5UcnL"
X Link 2021-07-28T18:19Z [---] followers, [--] engagements

"We joined renowned #oncology experts for our R&D Day and provided an extensive update on our viral #immunotherapy pipeline including new #data from our #NSCLC and #HGG programs. Read highlights in the PR and view the event recording here: https://bit.ly/3UGwheG https://bit.ly/3UGwheG"
X Link 2022-12-07T19:29Z [---] followers, [--] engagements

"This #CancerPreventionMonth we honor the power of research education and early action in fighting cancer. Our off-the-shelf multimodal immunotherapies harness the immune system to fight cancer. Together we're working to bring new treatment options to those who need them"
X Link 2026-02-13T15:00Z [---] followers, [---] engagements

"Were thrilled to announce that Candel has been honored at the Scrip Awards [----] This recognition celebrates our successful phase [--] study of CAN-2409 in localized prostate cancer. Thank you to @Citeline for this honor. https://www.citeline.com/en/awards/scripawards https://www.citeline.com/en/awards/scripawards"
X Link 2025-12-12T13:34Z [---] followers, [----] engagements

"Another @ZEROCancer Run/Walk for the books Weather was poor but celebrations persisted in the Hampton Roads community and we were thrilled to take part in a great cause #endprostatecancer"
X Link 2019-11-21T16:17Z [---] followers, [--] engagements

"#ICYMI: Our CEO @PaulPeterTak discussed leveraging our viral platforms to stimulate immune responses in people living with #Cancer. Read more by our CEO here: https://bit.ly/3iA8c7Z https://bit.ly/3iA8c7Z"
X Link 2021-02-08T21:16Z [---] followers, [--] engagements

"#ICYMI Earlier this month we announced our sponsorship of @WESTorg a group that helps early to mid-career women develop business & leadership skills and grow professional networks. At Candel we are committed in our support for #women leaders in #STEM: https://bit.ly/3rmXcOe https://bit.ly/3rmXcOe"
X Link 2021-03-25T15:06Z [---] followers, [--] engagements

"For #CancerImmunotherapyMonth we join in raising awareness for discoveries of potential treatments and remain committed to our mission to save extend and improve the lives of patients through oncolytic viral #immunotherapies #Immune2Cancer"
X Link 2021-06-03T18:23Z [---] followers, [--] engagements

"Today were pleased to announce the pricing of our #IPO. We share this pivotal milestone with our employees investors and partners as their continued efforts enabled this achievement. Collectively we can light the way for new discoveries and aspire to improve patient lives"
X Link 2021-07-27T12:02Z [---] followers, [--] engagements

"#ICYMI Candel is now part of the @Nasdaq family Were excited to share this moment with our dedicated employees and look forward to continuing our purpose to save extend and improve the lives of patients through oncolytic viral #immunotherapies. #IPO $CADL"
X Link 2021-08-03T16:00Z [---] followers, [--] engagements

"Congratulations to our incredible team on this milestone today We are excited to ring in a new era for Candel and take the next step as a public company"
X Link 2021-08-20T13:27Z [---] followers, [--] engagements

"Lead investigator @CharuAggarwalMD and Candel present phase [--] #data on CAN-2409 showing cytotoxic T cell response & disease control in patients with #NSCLC at #ASCO22. View our poster here: https://www.candeltx.com/wp-content/uploads/news/Candel-ASCO-2022.pdf https://www.candeltx.com/wp-content/uploads/news/Candel-ASCO-2022.pdf"
X Link 2022-06-06T16:12Z [---] followers, [--] engagements

"Join us in welcoming the recently appointed members of our Board of Directors Dr. Gary Nabel Renee Gaeta & Joseph Papa Each members expertise will prove invaluable as we continue developing novel oncolytic viral #immunotherapies for patients in need. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-three-new-members-its-board https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-appoints-three-new-members-its-board"
X Link 2022-08-01T12:04Z [---] followers, [--] engagements

"We hope to shine a light on the challenges faced patients w/ #ProstateCancer & provide support through new promising investigational treatment options. Learn how Luis and the team leverage their expertise to positively impact the community: #ProstateCancerAwarenessMonth"
X Link 2022-09-19T16:41Z [---] followers, [--] engagements

"We've partnered w/ @Penn Center for Cellular Immunotherapies to study novel viral #immunotherapies in combo w/ CAR-T cell therapies for #solidtumors via our enLIGHTEN Discovery Platform. Learn more about the partnership & our newly debuted platform: https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-partners-university-pennsylvanias-center https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-partners-university-pennsylvanias-center"
X Link 2022-10-26T12:06Z [---] followers, [--] engagements

"Save the date On December [--] our leadership team will join renowned experts in #oncology for our virtual R&D Day where well conduct an in-depth review of our viral #immunotherapy platforms and late-stage clinical pipeline. Stay tuned for further details"
X Link 2022-11-21T17:36Z [---] followers, [--] engagements

"During our R&D Day on Dec. [--] we will provide an overview of our viral #immunotherapy approach and #oncology pipeline including new data from our phase [--] clinical trial of CAN-2409 with anti-PD-1 agents in patients with late-stage #NSCLC. Read more here: https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-day-december-6-2022 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-host-virtual-rd-day-december-6-2022"
X Link 2022-11-29T13:02Z [---] followers, [--] engagements

"Candel has arrived in #SanFrancisco for the 41st Annual @jpmorgan Healthcare Conference to discuss our exciting pipeline of viral #immunotherapies with investors and industry colleagues. Let us know if youll be at #JPM23 and would like to connect"
X Link 2023-01-09T18:41Z [---] followers, [----] engagements

"Listen below as our CEO @PaulPeterTak speaks to our commitment to #patients & how we're developing investigational viral #immunotherapies to save improve & extend the lives of those impacted by hard-to-treat #cancers: #CAN2409 #ProstateCancer https://bit.ly/3XiTDZQ https://bit.ly/3XiTDZQ"
X Link 2023-01-11T18:34Z [---] followers, [---] engagements

"This #InternationalDayofWomenandGirlsinScience wed like to highlight our CSO Dr. @baroneExpMed who led development of our enLIGHTEN Discovery Platform designed to discover and develop novel viral #immunotherapies for solid #tumors. Hear more from her below. #WomenInScience"
X Link 2023-02-11T17:05Z [---] followers, [---] engagements

"President & CEO @paulpetertak MD PhD FMedSci will serve as a keynote speaker and discuss Candels strategic approach developing viral immunotherapies to treat cancer at the Targeting share mechanisms in immune-mediated inflammatory diseases Grantees symposium this week"
X Link 2023-07-13T17:03Z [---] followers, [---] engagements

"We are pleased to report updated data from our phase [--] clinical trial of CAN-2409 in non-small cell lung cancer. These initial data demonstrate an encouraging number of survivors and a favorable safety profile for CAN-2409. Read more here: https://bit.ly/48qstGB https://bit.ly/48qstGB"
X Link 2023-09-26T12:07Z [---] followers, [----] engagements

"Watch our Principal Investigator @EAChiocca discuss the newest CAN-3110 scientific publication in Nature. We are honored to see the progress of our investigational viral immunotherapy and look forward to developing it in the future. Read the publication: https://bit.ly/3s0t55v Honored to be featured this evening on @WCVB NewsCenter [--] at [--] highlighting our teams advances on treating #Glioblastoma. 📸🧠 https://t.co/vfT9304Kid https://bit.ly/3s0t55v Honored to be featured this evening on @WCVB NewsCenter [--] at [--] highlighting our teams advances on treating #Glioblastoma. 📸🧠"
X Link 2023-10-21T00:44Z [---] followers, [----] engagements

"President and CEO @paulpetertak MD PhD FMedSci will discuss the potential of viral immunotherapies as a cutting-edge approach to treating cancer in a webinar with Endpoints News tomorrow at 11:00 a.m. ET. Learn more or register here: https://webinars.endpts.com/can-oncolytic-viruses-make-a-comeback/source=Early-Edition https://webinars.endpts.com/can-oncolytic-viruses-make-a-comeback/source=Early-Edition"
X Link 2023-11-07T14:00Z [---] followers, [---] engagements

"We are pleased to share that @BrighamWomens will present clinical results on our oncolytic virus CAN-3110 in recurrent high-grade glioma highlighting extended survival associated with immune activation at #SNO2023. Learn more here: https://sno2023.eventscribe.net/ https://sno2023.eventscribe.net/"
X Link 2023-11-17T14:00Z [---] followers, [---] engagements

"Candel is pleased to announce the U.S. FDA granted Fast Track Designation for its lead investigational medicine CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with borderline resectable PDAC to improve overall survival. Read more: https://bit.ly/4akp3q3 https://bit.ly/4akp3q3"
X Link 2023-12-12T13:08Z [---] followers, [---] engagements

"President and CEO @paulpetertak MD PhD FMedSci will discuss the potential of $CADL's investigational medicine CAN-3110 as a well-tolerated and active cancer treatment at the Oncolytic Virotherapy Summit on December 13th at 4:15 pm ET. Learn more: https://bit.ly/3GoMwIW https://bit.ly/3GoMwIW"
X Link 2023-12-13T14:00Z [---] followers, [---] engagements

"We're excited about the transformative potential of our promising and diversified immunotherapy pipeline. [----] will be a year of great progress with an anticipated six data readouts across our three innovative platforms. Learn more here: https://bit.ly/3UsTKUb https://bit.ly/3UsTKUb"
X Link 2024-02-05T13:07Z [---] followers, [---] engagements

"President and CEO Paul Peter Tak MD PhD FMedSci discussed Candels development of multimodal biological immunotherapies to fight cancer and potentially alter the future of cancer immunotherapy in the below interview with Healthcare Future. https://bit.ly/3wzoJ7p https://bit.ly/3wzoJ7p"
X Link 2024-02-27T21:33Z [---] followers, [---] engagements

"We are pleased to share that we will unveil the second candidate from our enLIGHTEN Discovery Platform in a presentation at #AACR2024. Learn more about the presentation here: https://bit.ly/49EDfta https://bit.ly/49EDfta"
X Link 2024-03-05T21:42Z [---] followers, [---] engagements

"Brain science is critical to help lead healthier & more productive lives. At $CADL we know the importance of brain science and are developing our multimodal biological immunotherapy candidate CAN-3110 as a potential treatment for brain cancer. #BrainAwarenessWeek"
X Link 2024-03-11T13:00Z [---] followers, [---] engagements

"CSO Francesca Barone MD PhD will discuss how Candels multimodal biological immunotherapy candidate CAN-3110 has shown promising activity in treatment resistant HGG at the Glioblastoma Drug Development Summit. Learn more here: https://glioblastoma-drugdevelopment.com/ https://glioblastoma-drugdevelopment.com/"
X Link 2024-03-25T13:00Z [---] followers, [---] engagements

"2023 was a pivotal year for $CADL heightened by multiple data readouts demonstrating the potential for differentiated survival in combination with our clinical product candidates in multiple cancer types. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-fourth-quarter-and-full-year-2023 https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-fourth-quarter-and-full-year-2023"
X Link 2024-03-28T12:11Z [---] followers, [---] engagements

"We are pleased to share positive updated survival data from the P2 trial of CAN-2409 in non-metastatic pancreatic cancer. Data reveal notable improvements in median overall survival & safety supporting multiple injections of CAN-2409 were well tolerated. https://bit.ly/3xhLgWu https://bit.ly/3xhLgWu"
X Link 2024-04-04T12:06Z [---] followers, [----] engagements

"Were excited to unveil the second immunotherapy candidate from our enLIGHTEN Discovery Platform at #AACR2024. The first-in-class TLS-inducing multimodal immunotherapy candidate is being developed as a potential treatment for solid tumors. Read more https://bit.ly/3vK6w6W https://bit.ly/3vK6w6W"
X Link 2024-04-09T12:11Z [---] followers, [---] engagements

"We are pleased to share that CAN-2409 has received Orphan Drug Designation to treat pancreatic cancer. CAN-2409 has demonstrated the ability to significantly extend survival in pancreatic cancer patients and potentially change the treatment landscape. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-orphan-drug-designation-can https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-orphan-drug-designation-can"
X Link 2024-04-11T13:05Z [---] followers, [----] engagements

"#CancerControlMonth is a time to raise awareness support those battling cancer & advocate for prevention & additional research to combat this disease. Were developing viral immunotherapies to empower an individuals immune system to stand against cancer. https://bit.ly/3poKtPy https://bit.ly/3poKtPy"
X Link 2024-04-23T13:00Z [---] followers, [---] engagements

"We are pleased to share that two abstracts were accepted for presentation at #ASCO2024. Presentations will highlight ph [--] topline OS data for CAN-2409 in NSCLC and a trials in progress update on the ph 1b trial of CAN-3110 in recurrent high-grade glioma. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-upcoming-presentations-2024-asco https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-upcoming-presentations-2024-asco"
X Link 2024-04-25T12:10Z [---] followers, [----] engagements

"In honor of National #VolunteerMonth Candel is celebrating the power of giving back. Whether it's lending a hand at a soup kitchen mentoring youth or cleaning up parks every act makes a difference. Let's inspire kindness & compassion together #NationalVolunteerMonth"
X Link 2024-04-26T13:00Z [---] followers, [---] engagements

"We are seeing steady advancement across our pipeline of clinical and preclinical programs and are excited for whats to come. Learn about our Q1 progress and anticipated plans for the rest of the year in our Q1 [----] financial press release: https://bit.ly/44Ii9IH https://bit.ly/44Ii9IH"
X Link 2024-05-14T12:06Z [---] followers, [----] engagements

"We will present positive data from the P2 trial of CAN-2409 in NSCLC demonstrating a mOS of [----] months compared to published results of mOS of [----] months observed in a similar historical control patient population #ASCO2024. Read more https://bit.ly/4bRlBTK https://bit.ly/4bRlBTK"
X Link 2024-05-24T12:00Z [---] followers, [----] engagements

"We are pleased that the US FDA has granted Orphan Drug Designation to CAN-3110 for the treatment of rHGG. This designation builds on the momentum of the Fast Track Designation & reinforces the potential of CAN-3110 as a treatment option for rHGG patients. https://bit.ly/3KHNQZD https://bit.ly/3KHNQZD"
X Link 2024-05-30T12:04Z [---] followers, [----] engagements

"We presented a poster with positive data from the P2 trial of CAN-2409 in #NSCLC demonstrating a mOS of [----] months compared to published results of mOS of [----] months observed in a similar historical control patient population at #ASCO2024. https://bit.ly/45bwIow https://bit.ly/45bwIow"
X Link 2024-06-03T20:46Z [---] followers, [----] engagements

"President and CEO @paulpetertak MD PhD FMedSci will share the latest company updates from $CADL at the Jefferies Global Healthcare Conference on Wednesday June [--] [----] at 5:30 p.m. ET. Listen to the live or archived presentation here: https://bit.ly/3OHUqm0 https://bit.ly/3OHUqm0"
X Link 2024-06-04T13:00Z [---] followers, [----] engagements

"#ICYMI the $CADL team hosted a breakfast panel at #ASCO2024 to review their highly anticipated poster presentation highlighting positive overall survival data from the phase [--] trial of CAN-2409 in #NSCLC. Listen to the event replay here: https://bit.ly/3wQANli https://bit.ly/3wQANli"
X Link 2024-06-04T18:14Z [---] followers, [----] engagements

"President and CEO @paulpetertak MD PhD FMedSci will moderate a panel discussion with fellow life Science CEOs on Managing the Runway at the @LongwoodLeaders Spring MIT conference on Tues June 18th at 10:50 a.m. ET. Learn more here: https://bit.ly/45DSAZX https://bit.ly/45DSAZX"
X Link 2024-06-14T13:00Z [---] followers, [---] engagements

"President and CEO @paulpetertak MD PhD FMedSci will discuss the latest company updates from $CADL at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday June [--] [----] at 3:00 p.m. ET. Listen to the discussion here: https://bit.ly/3OHUqm0 https://bit.ly/3OHUqm0"
X Link 2024-06-21T13:00Z [---] followers, [---] engagements

"President and CEO @paulpetertak MD PhD FMedSci joined other industry experts in a discussion on the evolution of cancer vaccines in a 3-part series with @medicine_maker. Learn more about cancer vaccines how they work and whats to come here: https://bit.ly/4eMYwUh https://bit.ly/4eMYwUh"
X Link 2024-07-01T20:47Z [---] followers, [---] engagements

"Wishing everyone a fun and safe 4th of July holiday. Happy Independence Day #IndependenceDay #4thofJuly"
X Link 2024-07-04T13:00Z [---] followers, [---] engagements

"Glioblastoma Awareness Day is dedicated to raising awareness for the most common and deadliest type of brain cancer. At $CADL were developing our viral immunotherapy candidate CAN-3110 as a potential treatment for glioblastoma. https://bit.ly/3Y84GbL https://bit.ly/3Y84GbL"
X Link 2024-07-17T20:06Z [---] followers, [----] engagements

"Were excited about the progress made across our pipeline of promising cancer immunotherapy candidates. Clinical advancements coupled with key regulatory achievements have set a strong foundation for what we expect to be a pivotal year of growth. https://bit.ly/3Ax7OnJ https://bit.ly/3Ax7OnJ"
X Link 2024-08-13T12:15Z [---] followers, [---] engagements

"It is estimated that there will be approx. 299k new cases of #prostatecancer cases in the United States in [----]. At $CADL we're advancing our viral immunotherapy CAN-2409 designed to empower the immune system to fight cancer including #prostatecancer more effectively"
X Link 2024-09-05T13:00Z [---] followers, [----] engagements

"President and CEO @paulpetertak MD PhD FMedSci will discuss the latest company updates from Candel in a presentation at the H.C. Wainwright Annual Global Investment Conference. Listen to the presentation available on-demand here: https://bit.ly/3OHUqm0 https://bit.ly/3OHUqm0"
X Link 2024-09-09T13:00Z [---] followers, [---] engagements

"President and CEO @paulpetertak MD PhD FMedSci will chair a panel with other experts to discuss the improvements and new approaches to treating autoimmune and inflammatory diseases at the @BioCentury Grand Grounds. Learn more: https://bit.ly/3AFx6QJ https://bit.ly/3AFx6QJ"
X Link 2024-09-11T13:00Z [---] followers, [---] engagements

"On #WorldCancerResearchDay we honor the relentless pursuit of innovation in the fight against cancer. We're developing 2nd generation viral immunotherapies to empower the immune system to combat cancer. Join us as we push the boundaries of science and bring new hope. #WCRD2024"
X Link 2024-09-24T13:00Z [---] followers, [---] engagements

"We're committed to improving outcomes for #prostatecancer patients. CEO @paulpetertak discusses the need for better early-stage disease treatments & shares his thoughts on patient-centered innovation & the future of prostate cancer care in @MedCityNews. https://medcitynews.com/2024/09/prostate-cancer-management-we-need-better-options-for-early-stage-disease/ https://medcitynews.com/2024/09/prostate-cancer-management-we-need-better-options-for-early-stage-disease/"
X Link 2024-10-03T14:15Z [---] followers, [---] engagements

"Our team is presenting a poster on CAN-3110s activity in a model of #melanoma at @sitcancer 39th Annual Meeting See the details here: #SITC24 $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-therapeutic https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-therapeutic"
X Link 2024-10-04T13:15Z [---] followers, [----] engagements

"President and CEO @paulpetertak MD PhD FMedSci will join a panel with Sushil Patel CEO of Replimune at the ROTH Healthcare Opportunities Conference. The panel will cover product differentiation data across indications development steps & manufacturing capabilities"
X Link 2024-10-07T14:15Z [---] followers, [---] engagements

"Only 15-40% of advanced #NSCLC patients respond to standard ICIs. This #HealthyLungMonth we're highlighting the need for new treatments. Candel is testing CAN-2409 a viral immunotherapy showing promise in progressive disease despite ICI treatment. https://www.candeltx.com/patients/#step-25 https://www.candeltx.com/patients/#step-25"
X Link 2024-10-10T15:00Z [---] followers, [---] engagements

"President and CEO @paulpetertak MD PhD FMedSci shares insights on our CAN-3110 clinical program for recurrent #glioblastoma with DocWire News. Watch to learn more. $CADL https://docwirenews.com/post/paul-peter-tak-ceo-of-candel-therapeutics-discusses-the-treatment-of-glioblastoma https://docwirenews.com/post/paul-peter-tak-ceo-of-candel-therapeutics-discusses-the-treatment-of-glioblastoma"
X Link 2024-10-17T12:59Z [---] followers, [----] engagements

"Were presenting initial data based on our ph1b trial of multiple injections with CAN-3110 in recurrent #gliomblastoma advances based on the enLIGHTEN Discovery Platform & our new immunotherapy that induces tertiary lymphoid structures in solid tumors. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-innovative-cancer-therapy https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-showcases-innovative-cancer-therapy"
X Link 2024-10-28T13:05Z [---] followers, [---] engagements

"Over [---] million Americans are living with a #braintumor. Brain Tumor Awareness Week is dedicated to raising #awareness about the challenges faced by those diagnosed highlighting the need for specialized responses and for increased research efforts. https://theibta.org/awareness-raising/ibtaw-toolkit/ https://theibta.org/awareness-raising/ibtaw-toolkit/"
X Link 2024-10-29T14:00Z [---] followers, [---] engagements

"We're presenting preclinical data on CAN-3110 in a #melanoma model at #SITC24 Our poster will highlight: Potent antitumor activity Immune activation Potential expansion beyond high-grade glioma More details: $CADL #CancerResearch @sitcancer https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-sitc-annual-meeting https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-sitc-annual-meeting"
X Link 2024-11-05T14:09Z [---] followers, [----] engagements

"We are seeing steady advancement across our pipeline and look forward to continued momentum as we head into [----]. Learn about our Q3 progress and anticipated plans for the rest of the year in our Q3 [----] financial press release: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2024-financial-results https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2024-financial-results"
X Link 2024-11-14T13:10Z [---] followers, [----] engagements

"President and CEO @paulpetertak MD PhD FMedSci will share the latest corporate updates at the @Jefferies London Healthcare Conference this week. Listen to the live or archived presentation here: $CADL #JefferiesHealthcare https://ir.candeltx.com/news-and-events/events-and-presentations https://ir.candeltx.com/news-and-events/events-and-presentations"
X Link 2024-11-18T13:51Z [---] followers, [----] engagements

"President and CEO @paulpetertak MD PhD FMedSci is delivering a keynote at the @britsocimm Immune Therapies Summit next week in Cambridge Join us to explore breakthrough approaches in immune therapeutics. #ImmuneTherapies24 #Immunology $CADL https://web-eur.cvent.com/event/ffa03d05-261d-41c7-9633-186758c1883b/summarytm=_B4a8-iJwdB-eiyRO4nk6r-wP4If9zTYweHKsyXJqSY https://web-eur.cvent.com/event/ffa03d05-261d-41c7-9633-186758c1883b/summarytm=_B4a8-iJwdB-eiyRO4nk6r-wP4If9zTYweHKsyXJqSY"
X Link 2024-11-20T13:31Z [---] followers, [----] engagements

"This #WorldPancreaticCancerDay were highlighting our ph [--] clinical trial of CAN-2409 + standard care (SoC) in pancreatic cancer. Patients achieved estimated [----] months median survival in the CAN-2409 + SoC group vs [----] months in the SoC control group. https://www.candeltx.com/platforms/ https://www.candeltx.com/platforms/"
X Link 2024-11-21T14:54Z [---] followers, [---] engagements

"For men with localized #ProstateCancer treatment decisions are complex. While active surveillance prevents over-treatment in low-risk cases many see progression over time. We're exploring new approaches to bridge this gap through our phase 2b trial. https://www.candeltx.com/pipeline/ https://www.candeltx.com/pipeline/"
X Link 2024-11-22T15:00Z [---] followers, [---] engagements

"Did you know CAN-2409 our investigational viral immunotherapy is designed to trigger the bodys anti-tumor immune response when combined with valacyclovir. Prostate data readouts expected later this year. Learn how CAN-2409 works: $CADL https://www.candeltx.com/pipeline/ https://www.candeltx.com/pipeline/"
X Link 2024-11-25T15:34Z [---] followers, [----] engagements

"Could CAN-2409 change how we treat localized #ProstateCancer Our P3 trial evaluates CAN-2409 an investigational immunotherapy for patients with intermediate-high risk prostate cancer. Our goal is disease-free survival. Learn more: $CADL https://www.candeltx.com/pipeline/ https://www.candeltx.com/pipeline/"
X Link 2024-11-27T15:00Z [---] followers, [----] engagements

"Candel is proud to participate in #Movember supporting vital awareness for men's health initiatives. This cause resonates deeply with our mission as we advance our clinical trials in prostate cancer treatment. #MensHealth #ProstateCancer $CADL https://us.movember.com/ https://us.movember.com/"
X Link 2024-11-29T15:00Z [---] followers, [----] engagements

"Our CMO Garrett Nichols M.D. M.S. discusses our phase [--] trial of CAN-2409 - potentially the first new treatment for localized prostate cancer in decades. Watch: #ProstateCancer $CADL https://www.youtube.com/watchv=iv3HFVKsunM https://www.youtube.com/watchv=iv3HFVKsunM"
X Link 2024-12-10T21:02Z [---] followers, [----] engagements

"Were proud to announce topline data from our pivotal P3 trial investigating CAN-2409 in intermediate-high risk localized prostate cancer a key milestone in our mission to develop innovative treatment options for cancer patients. See the results: $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-can-2409-achieved-primary-endpoint https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-can-2409-achieved-primary-endpoint"
X Link 2024-12-11T15:46Z [---] followers, [----] engagements

"As [----] draws to a close we're grateful for our team partners & the patients who inspire us. Wishing everyone a peaceful holiday season & continued hope in advancing cancer treatment. #BiotechCommunity #Innovation $CADL"
X Link 2024-12-23T15:00Z [---] followers, [----] engagements

"2024 brought positive topline data readouts for our phase [--] prostate cancer clinical trial and encouraging results across our pipeline. As we welcome [----] we're energized by our progress in advancing novel cancer treatments. Here's to continuing our mission in the new year"
X Link 2025-01-02T15:00Z [---] followers, [----] engagements

"Entering [----] with strong momentum Successes in [----] include positive P3 data for CAN-2409 in prostate cancer & encouraging survival data in pancreatic cancer & NSCLC. We remain focused on advancing viral immunotherapies to help patients fight cancer. https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-provides-corporate-update-and-highlights https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-provides-corporate-update-and-highlights"
X Link 2025-01-13T13:05Z [---] followers, [----] engagements

"Our enLIGHTEN Discovery Platform represents a revolutionary step forward in viral immunotherapy development. This systematic data-driven platform combines advanced analytics with human biology to create precisely engineered HSV-based gene constructs. https://www.candeltx.com/platforms/ https://www.candeltx.com/platforms/"
X Link 2025-01-16T15:15Z [---] followers, [----] engagements

"ICYMI: In [----] we successfully completed our public offering raising $92M to advance our cancer treatment pipeline including BLA preparation for CAN-2409 in prostate cancer. Thank you for supporting our mission #BiotechNews $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-closing-public-offering-and-full https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-closing-public-offering-and-full"
X Link 2025-01-23T15:09Z [---] followers, [---] engagements

"ICYMI: We're starting [----] with strong momentum & clear direction. Our lead candidate CAN-2409 shows promising phase [--] results in prostate cancer. We're advancing toward BLA submission with clear momentum and $103M to fund operations into Q1 [----]. $CADL https://www.proactiveinvestors.com/companies/news/1064164/candel-therapeutics-advancing-lead-candidate-targeting-prostate-cancer-towards-fda-submission-1064164.html https://www.proactiveinvestors.com/companies/news/1064164/candel-therapeutics-advancing-lead-candidate-targeting-prostate-cancer-towards-fda-submission-1064164.html"
X Link 2025-02-04T17:55Z [---] followers, [----] engagements

"We're approaching an important milestone in our pancreatic cancer program. Updated overall survival data from our phase 2a clinical trial of CAN-2409 is expected this quarter. Stay tuned for updates on this program $CADL"
X Link 2025-02-14T14:30Z [---] followers, [----] engagements

"Fireside chat: Our CEO @paulpetertak discusses CAN-2409's positive phase [--] results in prostate cancer and Candel's full oncology pipeline with HCW Research Analyst Vernon Bernardino. View here: #CancerResearch #BioTech $CADL https://ir.candeltx.com/events/event-details/hc-wainwright-home-fireside-chat-w-dr-paul-peter-tak-ceo-candel-therapeutics https://ir.candeltx.com/events/event-details/hc-wainwright-home-fireside-chat-w-dr-paul-peter-tak-ceo-candel-therapeutics"
X Link 2025-02-18T15:30Z [---] followers, [----] engagements

"This #CancerPreventionMonth we recognize the importance of research education and community support in the fight against cancer. As we develop new therapeutic options we stand with patients healthcare providers and researchers united to transform cancer care"
X Link 2025-02-20T14:30Z [---] followers, [----] engagements

"Today we have announced positive final survival data from our phase [--] clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Data showed median overall survival of [----] months with CAN-2409 vs. [----] months in control group. $CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-positive-final-survival-data https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-positive-final-survival-data"
X Link 2025-02-25T16:12Z [---] followers, [----] engagements

"Investigational medicine CAN-3110 is breaking new ground in treating high-grade glioma. Engineered to target cancer cells while protecting healthy brain tissue with promising clinical activity in a phase 1b clinical trial. $CADL https://www.candeltx.com/platforms/ https://www.candeltx.com/platforms/"
X Link 2025-02-26T15:41Z [---] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing